☆ 4.7 Editorial Material

The Elusive Prize of Radiation Therapy Predictive Assays in Breast Cancer

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2023)

The Clinical Utility of DCISionRT(R) on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery

Chirag Shah et al.

Summary: The DCISionRT testing significantly impacted clinicians' recommendations for adjuvant radiation therapy in DCIS patients, leading to changes in the recommended treatment for a significant percentage of patients. The DCISionRT score risk group had the strongest association with radiation therapy recommendations, with other factors such as patient preference, tumor size, and grade also playing a role in decision-making.

ANNALS OF SURGICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma In Situ (DCIS) of the Breast, in a Randomized Clinical Trial (SweDCIS)

Fredrik Waernberg et al.

Summary: Although clinical advancements in the diagnosis and treatment of ductal carcinoma in situ (DCIS) have been made, determining who will benefit from radiotherapy (RT) remains a challenge. DCISionRT is able to identify women at high risk of recurrence and provide beneficial RT treatment for them, while also determining that women at low risk of recurrence do not benefit significantly from RT.

CANCERS (2021)

添加到收藏夹

Article Oncology

Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804

Beryl McCormick et al.

Summary: NRG/RTOG 9804 is the only randomized trial assessing the impact of whole breast irradiation versus observation in women with good-risk ductal carcinoma in situ (DCIS) following lumpectomy. The study found that whole breast irradiation significantly reduced the risk of ipsilateral breast recurrence for DCIS with durable effects at 15 years.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Validation of a Ductal Carcinoma In Situ Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy

Sheila Weinmann et al.

CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Article Oncology

Abstract GS5-08: A validation of DCIS biological risk profile in a randomised study for radiation therapy with 20 year follow-up (SweDCIS)

F Wärnberg et al.

CANCER RESEARCH (2018)

添加到收藏夹

Article Oncology

A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk

Troy Bremer et al.

CLINICAL CANCER RESEARCH (2018)

添加到收藏夹

Review Medicine, General & Internal

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration

Douglas G. Altman et al.

PLOS MEDICINE (2012)

添加到收藏夹

The Elusive Prize of Radiation Therapy Predictive Assays in Breast Cancer

相关参考文献

The Clinical Utility of DCISionRT(R) on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery

Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma In Situ (DCIS) of the Breast, in a Randomized Clinical Trial (SweDCIS)

Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804

Validation of a Ductal Carcinoma In Situ Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy

Abstract GS5-08: A validation of DCIS biological risk profile in a randomised study for radiation therapy with 20 year follow-up (SweDCIS)

A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration

导出引文

分享论文